DrugCite
Search

PAZOPANIB

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Pazopanib Adverse Events Reported to the FDA Over Time

How are Pazopanib adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Pazopanib, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Pazopanib is flagged as the suspect drug causing the adverse event.

Most Common Pazopanib Adverse Events Reported to the FDA

What are the most common Pazopanib adverse events reported to the FDA?

Fatigue
342 (3.73%)
Diarrhoea
328 (3.58%)
Death
286 (3.12%)
Nausea
279 (3.04%)
Vomiting
189 (2.06%)
Pyrexia
147 (1.6%)
Dyspnoea
143 (1.56%)
Hypertension
134 (1.46%)
Decreased Appetite
127 (1.39%)
Alanine Aminotransferase Increased
113 (1.23%)
Asthenia
111 (1.21%)
Show More Show More
Blood Pressure Increased
103 (1.12%)
Dehydration
102 (1.11%)
Drug Ineffective
98 (1.07%)
Anaemia
95 (1.04%)
Disease Progression
88 (.96%)
Abdominal Pain
87 (.95%)
Aspartate Aminotransferase Increase...
86 (.94%)
Headache
85 (.93%)
Abdominal Pain Upper
71 (.77%)
Blood Bilirubin Increased
70 (.76%)
Pulmonary Embolism
68 (.74%)
Hepatic Enzyme Increased
67 (.73%)
Cough
65 (.71%)
Pneumonia
65 (.71%)
Thrombocytopenia
65 (.71%)
Weight Decreased
64 (.7%)
Hair Colour Changes
63 (.69%)
Liver Function Test Abnormal
58 (.63%)
Neoplasm Malignant
52 (.57%)
Pain
52 (.57%)
Back Pain
51 (.56%)
Malaise
51 (.56%)
Constipation
49 (.53%)
Dizziness
49 (.53%)
Rash
49 (.53%)
Confusional State
43 (.47%)
Jaundice
43 (.47%)
Alopecia
41 (.45%)
Dysgeusia
41 (.45%)
General Physical Health Deteriorati...
41 (.45%)
Hypotension
41 (.45%)
Off Label Use
40 (.44%)
Sepsis
40 (.44%)
Febrile Neutropenia
38 (.41%)
Pain In Extremity
38 (.41%)
Pleural Effusion
38 (.41%)
Renal Failure
38 (.41%)
Hepatotoxicity
36 (.39%)
Infection
36 (.39%)
Blood Alkaline Phosphatase Increase...
35 (.38%)
Blood Creatinine Increased
35 (.38%)
Chest Pain
35 (.38%)
Renal Cancer
32 (.35%)
Gamma-glutamyltransferase Increased
31 (.34%)
Haemoptysis
31 (.34%)
Hepatic Function Abnormal
31 (.34%)
Neutropenia
31 (.34%)
Oedema Peripheral
31 (.34%)
Hypothyroidism
29 (.32%)
Mucosal Inflammation
29 (.32%)
Hyponatraemia
28 (.31%)
Palmar-plantar Erythrodysaesthesia ...
28 (.31%)
Pericardial Effusion
28 (.31%)
Stomatitis
28 (.31%)
Muscle Spasms
27 (.29%)
Convulsion
26 (.28%)
Deep Vein Thrombosis
26 (.28%)
Pancreatitis
26 (.28%)
Renal Failure Acute
26 (.28%)
Urinary Tract Infection
26 (.28%)
Abdominal Discomfort
25 (.27%)
Haemoglobin Decreased
25 (.27%)
Hepatic Failure
25 (.27%)
Hospitalisation
25 (.27%)
Tachycardia
25 (.27%)
Cerebrovascular Accident
24 (.26%)
Pneumothorax
24 (.26%)
Pruritus
24 (.26%)
Adverse Drug Reaction
23 (.25%)
Arthralgia
23 (.25%)
Muscular Weakness
23 (.25%)
Visual Impairment
23 (.25%)
Adverse Event
22 (.24%)
Ileus
22 (.24%)
Platelet Count Decreased
22 (.24%)
Fall
21 (.23%)
Gait Disturbance
21 (.23%)
Ill-defined Disorder
21 (.23%)
Chills
20 (.22%)
Dyspepsia
20 (.22%)
Epistaxis
20 (.22%)
Haemorrhage
20 (.22%)
Lung Disorder
20 (.22%)
Blister
19 (.21%)
Chromaturia
19 (.21%)
Dysphonia
19 (.21%)
Malignant Neoplasm Progression
19 (.21%)
Mental Status Changes
19 (.21%)
Ageusia
18 (.2%)
Cardiac Failure Congestive
18 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Pazopanib, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pazopanib is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Pazopanib

What are the most common Pazopanib adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Pazopanib, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pazopanib is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Pazopanib According to Those Reporting Adverse Events

Why are people taking Pazopanib, according to those reporting adverse events to the FDA?

Renal Cell Carcinoma
625
Renal Cancer
360
Product Used For Unknown Indication
341
Sarcoma
168
Neoplasm
145
Metastatic Renal Cell Carcinoma
112
Show More Show More
Non-small Cell Lung Cancer
99
Renal Cancer Metastatic
80
Neoplasm Malignant
76
Ovarian Cancer
45
Malignant Glioma
38
Thyroid Cancer
32
Malignant Soft Tissue Neoplasm
31
Lung Neoplasm Malignant
24
Malignant Neoplasm Progression
14
Breast Cancer
14
Colorectal Cancer Metastatic
14
Drug Use For Unknown Indication
14
Leiomyosarcoma
13
Malignant Urinary Tract Neoplasm
12
Bladder Cancer
11
Ovarian Neoplasm
11
Cervix Carcinoma
11
Dermatofibrosarcoma
10
Prostate Cancer
10
Small Cell Lung Cancer Stage Unspec...
10
Neuroendocrine Tumour
10
Inflammatory Carcinoma Of The Breas...
9
Breast Cancer Metastatic
8
Gastrointestinal Cancer Metastatic
8
Gastrointestinal Stromal Tumour
8
Breast Neoplasm
7
Angiosarcoma
6
Lung Cancer Metastatic
6
Hepatic Neoplasm Malignant
6
Uterine Cancer
5
Synovial Sarcoma
5
Sarcoma Metastatic
5
Adrenal Carcinoma
4
Malignant Neoplasm Of Renal Pelvis
4
Synovial Sarcoma Metastatic
4
Chondrosarcoma
4
Transitional Cell Cancer Of The Ren...
4
Colorectal Cancer
4
Desmoplastic Small Round Cell Tumou...
3
Endometrial Sarcoma
3
Chondrosarcoma Metastatic
3
Female Reproductive Neoplasm
3
Bronchial Carcinoma
3
Malignant Melanoma
3
Leiomyosarcoma Metastatic
3

Drug Labels

LabelLabelerEffective
VotrientGlaxoSmithKline LLC27-FEB-13

Pazopanib Case Reports

What Pazopanib safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Pazopanib. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Pazopanib.